{
  "author": {
    "name": "Riley Griffin",
    "webUrl": "/author/profile/riley-griffin/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 29,
    "social": [],
    "articles": [
      {
        "uri": "/2023/12/08/biden-administration-says-it-can-seize-patents-of-costly-drugs/",
        "title": "Biden's pharma fix: New 'march-in' rule allows HHS to seize patents of pricey drugs",
        "byline": "Riley Griffin",
        "kicker": "News",
        "prettyDate": "December 08, 2023",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/12/Pharmaceutical-Manufacturer-Article-202312071508.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Pres. Biden's administration on Thursday unveiled a new framework allowing authorities the right to seize certain drug patents and license them to other manufacturers in order to lower drug prices.",
        "body": null
      },
      {
        "uri": "/2023/06/07/mark-cubans-drug-company-will-sell-costly-arthritis-drug-at-85-discount/",
        "title": "Humira biosimilar – at 85% discount – will be sold by Mark Cuban's drug company",
        "byline": "Riley Griffin",
        "kicker": "News",
        "prettyDate": "June 07, 2023",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/06/Mark-Cuban-Article-202306061522-1.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Coherus BioSciences will launch Yusimry – used to treat rheumatoid arthritis and psoriasis – which Cuban's Cost Plus Drugs will be offering starting in July.",
        "body": null
      },
      {
        "uri": "/2023/01/31/white-house-to-end-covid-19-public-health-emergency-on-may-11/",
        "title": "White House to end COVID-19 public health emergency on May 11",
        "byline": "Josh Wingrove and Riley Griffin",
        "kicker": "News",
        "prettyDate": "January 31, 2023",
        "timeToRead": "3 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2022/01/employees-mask-financial-work-covid.jpg",
          "width": "619",
          "height": "406"
        },
        "authors": [
          {
            "webUrl": "/author/profile/josh-wingrove/",
            "name": "Josh Wingrove"
          },
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The Biden administration had promised to give states 60 days notice before ending the public health emergency to allow sufficient time to prepare for changes to programs and regulatory authorities.",
        "body": null
      },
      {
        "uri": "/2021/11/25/jj-pharma-exec-reveals-playbook-for-stand-alone-drugmaker-412-124128/",
        "title": "J&J pharma exec lays out plans for stand-alone drug business",
        "byline": "Riley Griffin",
        "kicker": "Market Insights",
        "prettyDate": "November 25, 2021",
        "timeToRead": "4 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2021/11/Johnson-Johnson-logo-767x633.jpg",
          "width": "768",
          "height": "633"
        },
        "authors": [
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "Over the next decade, J&J will bet big on gene therapies.",
        "body": null
      },
      {
        "uri": "/2021/11/15/health-care-giant-jj-to-split-into-drug-consumer-companies-412-123842/",
        "title": "J&J latest health care giant to spin off consumer division",
        "byline": "Riley Griffin",
        "kicker": "News",
        "prettyDate": "November 15, 2021",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2021/11/Johnson-and-Johnson-767x633.jpg",
          "width": "768",
          "height": "633"
        },
        "authors": [
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Johnson & Johnson is following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market.",
        "body": null
      },
      {
        "uri": "/2020/10/30/covid-continues-to-put-a-damper-on-health-pharma-industries/",
        "title": "COVID continues to put a damper on health, pharma industries",
        "byline": "Emma Court, Robert Langreth, John Tozzi and Riley Griffin",
        "kicker": "Market Insights",
        "prettyDate": "October 30, 2020",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2020/10/covid-19-coronavirus-economy-money-chart-stocks.jpg",
          "width": "0",
          "height": "0"
        },
        "authors": [
          {
            "webUrl": "/author/profile/emma-court-robert-langreth-john-tozzi/",
            "name": "Emma Court, Robert Langreth, John Tozzi"
          },
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "For drugmakers, the pandemic has squeezed demand for everything from childhood vaccines to smoking-cessation drugs.",
        "body": null
      },
      {
        "uri": "/2020/09/14/trump-signs-new-executive-order-on-drug-prices-will-it-work/",
        "title": "Trump signs new executive order on drug prices",
        "byline": "Riley Griffin and Josh Wingrove",
        "kicker": "News",
        "prettyDate": "September 14, 2020",
        "timeToRead": "5 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2019/12/TrumpBloomberg.jpg",
          "width": "0",
          "height": "0"
        },
        "authors": [
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          },
          {
            "webUrl": "/author/profile/josh-wingrove/",
            "name": "Josh Wingrove"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The order comes after an earlier attempt to force pharmaceutical companies to make reductions didn't yield results.",
        "body": null
      },
      {
        "uri": "/2020/07/27/trump-executive-order-touts-most-far-reaching-prescription-drug-reforms-ever/",
        "title": "Trump executive order touts 'most far-reaching prescription drug reforms ever'",
        "byline": "Shira Stein, Riley Griffin and Jacquie Lee",
        "kicker": "News",
        "prettyDate": "July 27, 2020",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/05/DrugPricesShadow.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/shira-stein-riley-griffin/",
            "name": "Shira Stein, Riley Griffin"
          },
          {
            "webUrl": "/author/profile/jacquie-lee/",
            "name": "Jacquie Lee"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "New policies announced Friday aimed at lowering drug prices under Medicare would link prices to rates paid in other countries.",
        "body": null
      },
      {
        "uri": "/2020/06/12/46-states-accuse-drugmakers-of-price-collusion-in-latest-lawsuit/",
        "title": "46 states accuse drugmakers of price collusion in latest lawsuit",
        "byline": "David McLaughlin and Riley Griffin",
        "kicker": "News",
        "prettyDate": "June 12, 2020",
        "timeToRead": "5 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/12/DrugPriceFixing.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/david-mclaughlin/",
            "name": "David McLaughlin"
          },
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "The case is the third major complaint in a six-year investigation that accuses pharmaceutical companies of a widespread price-fixing.",
        "body": null
      },
      {
        "uri": "/2020/02/14/will-trump-use-executive-action-to-cut-drug-prices/",
        "title": "Will Trump use executive action to cut drug prices?",
        "byline": "Josh Wingrove and Riley Griffin",
        "kicker": "News",
        "prettyDate": "February 14, 2020",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2020/02/02032017-trump-ap.jpg",
          "width": "600",
          "height": "399"
        },
        "authors": [
          {
            "webUrl": "/author/profile/josh-wingrove/",
            "name": "Josh Wingrove"
          },
          {
            "webUrl": "/author/profile/riley-griffin/",
            "name": "Riley Griffin"
          }
        ],
        "kickerNode": [
          {
            "uri": "/news/",
            "sectionName": "News"
          }
        ],
        "summary": "Trump could force drug companies to accept lower payments from Medicare for treatments administered in doctors' offices.",
        "body": null
      }
    ]
  }
}